59 articles – 21 references  [version française]
Short view
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.
Moutel G., Duchange N., Raffi F., Sharara L. I., Theodorou I., Noël V., De Montgolfier S., Callies I., Bricaire F., Hervé C. et al
Eur J Hum Genet 13, 9 (2005) 1055-62 - http://www.hal.inserm.fr/inserm-00000049
 (15957002) 
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.
Grégoire Moutel () 1, Nathalie Duchange1, François Raffi2, Lama Sharara1, Ioannis Theodorou3, Violaine Noël4, Sandrine De Montgolfier1, Ingrid Callies1, François Bricaire5, Christian Hervé1, Catherine Leport4, The Aproco-Copilote Study Group
1:  LEM - Laboratoire d'éthique médicale et médecine légale
Université Paris V - Paris Descartes
Faculté de médecine, 45 rue des Saints-Pères, Paris 75006
France
2:  CISIH - Centre d'Information et de Soins de l'Immunodéficience Humaine
Hôtel Dieu 1 Place Alexis-Ricordeau 44035 Nantes Cedex
France
3:  Immunologie cellulaire et tissulaire
http://sirius.cervi.chups.jussieu.fr
INSERM : U543 – IFR113 – Université Pierre et Marie Curie (UPMC) - Paris VI
Gh Pitie-Salpetriere 83, Boulevard de L'Hopital 75013 PARIS
France
4:  Laboratoire de Recherche en Pathologie Infectieuse
Université Paris VII - Paris Diderot
16, rue Henri Huchard 75870 Paris cedex 18
France
5:  Service des maladies infectieuses et tropicales
Assistance publique - Hôpitaux de Paris (AP-HP) – Hôpital Pitié-Salpêtrière – Université Pierre et Marie Curie (UPMC) - Paris VI
47-83, boulevard de l'Hôpital 75651 PARIS Cedex 13
France
The aim of pharmacogenetic studies is to adapt therapeutic strategies to individual genetic profiles, thus maximising their efficacy and minimising the likelihood of adverse side effects. Since the advent of personalised medicine, the issue of communicating research results to participants has become increasingly important. We addressed this question in the context of HIV infection, as patients and associations are particularly concerned by research and therapeutic advances. We explored the standpoints of both research professionals and participants involved in a pharmacogenetic study conducted in a cohort of HIV-infected patients. The setting of the research protocol was followed over a 2-year period. Participants' standpoints were collected through a questionnaire and interviews were conducted with research professionals. Of 125 participants, 76% wished to receive individual results and 71% wished to receive collective results; 39% did not know when results might be expected. Communication of global research results is a principle that is generally accepted by professionals. Concerning individual feedback, the professionals felt that it was necessary if it could be of direct benefit to the participant, but they expressed doubts for situations with no recognised benefit. Our results highlight the necessity to consider this issue in greater detail. We suggest the need to anticipate the debates concerning individual feedback, to differentiate between situations and the importance of further investigations on the opportunities and modalities of communication. Finally, our work emphasised the opposite pressures between the pursuit of scientific knowledge and the therapeutic orientation of clinical trials.
Life Sciences/Ethics
Life Sciences/Human health and pathology/Infectious Diseases
Life Sciences/Genetics
English
1018-4813

Article in peer-reviewed journal
10.1038/sj.ejhg.5201450
Eur J Hum Genet
2005-09
13
9
1055-62

Attitude of Health Personnel – Attitude to Health – Communication – Controlled Clinical Trials – Ethics – Medical – Genetic Research – HIV Infections – Humans – Informed Consent – Interviews – Pharmacogenetics – Physician-Patient Relations – Questionnaires – Attitude o
Agence Nationale de Recherches sur le Sida (ANRS, Coordinating Action no. 7). Other supports: Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT, ex APPIT), Sidaction, Ensemble contre le Sida, and associated pharmaceutical companies.
Attached file list to this document: 
PDF
Moutel_et_al_EJHG.pdf(194.2 KB)
XHTML
index.xhtml(64.3 KB)